INDIVIDUAL ANTIPLATELET THERAPY IN PATIENTS WITH ATHEROSCLEROSIS OF LOWER EXTREMITIES: MYTH OR REALITY?

The incidence of atherosclerosis in the arteries of the lower extremities is increasing all over the world, and studies conducted in several countries have shown that increased incidence of chronic obliterating diseases of lower extremity arteries is associated with other cardiovascular events, and...

Full description

Bibliographic Details
Main Authors: O. V. Sirotkina, N. A. Surint, A. A. Topanova, T. V. Vavilova
Format: Article
Language:Russian
Published: Remedium Group LLC 2018-01-01
Series:Медицинский совет
Subjects:
Online Access:https://www.med-sovet.pro/jour/article/view/2225
_version_ 1797841692664004608
author O. V. Sirotkina
N. A. Surint
A. A. Topanova
T. V. Vavilova
author_facet O. V. Sirotkina
N. A. Surint
A. A. Topanova
T. V. Vavilova
author_sort O. V. Sirotkina
collection DOAJ
description The incidence of atherosclerosis in the arteries of the lower extremities is increasing all over the world, and studies conducted in several countries have shown that increased incidence of chronic obliterating diseases of lower extremity arteries is associated with other cardiovascular events, and with poor prognosis. The development of an algorithm for an integrated approach to treatment that will make it possible to personalize the drug therapy in this group of patients was one of the ways to improve the long-term results of reconstructive interventions on the arteries of the lower extremities. The study included 105 patients of both sexes (mean age 68 ± 1) who underwent reconstructive surgery on the arteries due to obliterating atherosclerosis of the lower extremities followed-up in the City Diagnostic Center No. 1 in St. Petersburg from 2008 until now. Before seeking treatment, all patients received acetylsalicylic acid (ASA) 100 mg per day as antiplatelet therapy.  The antiplatelet therapy was adjusted on the basis of clinical data, taking into account the laboratory and molecular genetic test results. The functional activity of platelets was monitored according to the ADP- and collagen-induced impedance aggregation indices.  Identification of genetic peculiarities of the drug metabolism and the factors that influence platelet aggregation and the simultaneous laboratory evaluation of the functional activity of platelets made it possible to achieve the stably low residual reactivity of platelets in all patients included in the study by assigning an individual regimen (ASA monotherapy, clopidogrel monotherapy, DAT) and doses (ASA 100 mg or 150 mg per day) of antiplatelet agents.
first_indexed 2024-04-09T16:35:26Z
format Article
id doaj.art-60eb898132784ece9d024d38b1b95fb6
institution Directory Open Access Journal
issn 2079-701X
2658-5790
language Russian
last_indexed 2024-04-09T16:35:26Z
publishDate 2018-01-01
publisher Remedium Group LLC
record_format Article
series Медицинский совет
spelling doaj.art-60eb898132784ece9d024d38b1b95fb62023-04-23T06:56:54ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902018-01-01020323910.21518/2079-701X-2017-20-32-392202INDIVIDUAL ANTIPLATELET THERAPY IN PATIENTS WITH ATHEROSCLEROSIS OF LOWER EXTREMITIES: MYTH OR REALITY?O. V. Sirotkina0N. A. Surint1A. A. Topanova2T. V. Vavilova3Almazov National Medical Research Centre of the Ministry of Health of Russia; Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia.City Diagnostic Center No 1.Almazov National Medical Research Centre of the Ministry of Health of Russia.Almazov National Medical Research Centre of the Ministry of Health of Russia; City Diagnostic Center No 1.The incidence of atherosclerosis in the arteries of the lower extremities is increasing all over the world, and studies conducted in several countries have shown that increased incidence of chronic obliterating diseases of lower extremity arteries is associated with other cardiovascular events, and with poor prognosis. The development of an algorithm for an integrated approach to treatment that will make it possible to personalize the drug therapy in this group of patients was one of the ways to improve the long-term results of reconstructive interventions on the arteries of the lower extremities. The study included 105 patients of both sexes (mean age 68 ± 1) who underwent reconstructive surgery on the arteries due to obliterating atherosclerosis of the lower extremities followed-up in the City Diagnostic Center No. 1 in St. Petersburg from 2008 until now. Before seeking treatment, all patients received acetylsalicylic acid (ASA) 100 mg per day as antiplatelet therapy.  The antiplatelet therapy was adjusted on the basis of clinical data, taking into account the laboratory and molecular genetic test results. The functional activity of platelets was monitored according to the ADP- and collagen-induced impedance aggregation indices.  Identification of genetic peculiarities of the drug metabolism and the factors that influence platelet aggregation and the simultaneous laboratory evaluation of the functional activity of platelets made it possible to achieve the stably low residual reactivity of platelets in all patients included in the study by assigning an individual regimen (ASA monotherapy, clopidogrel monotherapy, DAT) and doses (ASA 100 mg or 150 mg per day) of antiplatelet agents.https://www.med-sovet.pro/jour/article/view/2225obliterating atherosclerosis of the lower extremitiespersonalized antiplatelet therapyclopidogrelacetylsalicylic acidimpedance aggregometry
spellingShingle O. V. Sirotkina
N. A. Surint
A. A. Topanova
T. V. Vavilova
INDIVIDUAL ANTIPLATELET THERAPY IN PATIENTS WITH ATHEROSCLEROSIS OF LOWER EXTREMITIES: MYTH OR REALITY?
Медицинский совет
obliterating atherosclerosis of the lower extremities
personalized antiplatelet therapy
clopidogrel
acetylsalicylic acid
impedance aggregometry
title INDIVIDUAL ANTIPLATELET THERAPY IN PATIENTS WITH ATHEROSCLEROSIS OF LOWER EXTREMITIES: MYTH OR REALITY?
title_full INDIVIDUAL ANTIPLATELET THERAPY IN PATIENTS WITH ATHEROSCLEROSIS OF LOWER EXTREMITIES: MYTH OR REALITY?
title_fullStr INDIVIDUAL ANTIPLATELET THERAPY IN PATIENTS WITH ATHEROSCLEROSIS OF LOWER EXTREMITIES: MYTH OR REALITY?
title_full_unstemmed INDIVIDUAL ANTIPLATELET THERAPY IN PATIENTS WITH ATHEROSCLEROSIS OF LOWER EXTREMITIES: MYTH OR REALITY?
title_short INDIVIDUAL ANTIPLATELET THERAPY IN PATIENTS WITH ATHEROSCLEROSIS OF LOWER EXTREMITIES: MYTH OR REALITY?
title_sort individual antiplatelet therapy in patients with atherosclerosis of lower extremities myth or reality
topic obliterating atherosclerosis of the lower extremities
personalized antiplatelet therapy
clopidogrel
acetylsalicylic acid
impedance aggregometry
url https://www.med-sovet.pro/jour/article/view/2225
work_keys_str_mv AT ovsirotkina individualantiplatelettherapyinpatientswithatherosclerosisoflowerextremitiesmythorreality
AT nasurint individualantiplatelettherapyinpatientswithatherosclerosisoflowerextremitiesmythorreality
AT aatopanova individualantiplatelettherapyinpatientswithatherosclerosisoflowerextremitiesmythorreality
AT tvvavilova individualantiplatelettherapyinpatientswithatherosclerosisoflowerextremitiesmythorreality